Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab subcutaneous vs intravenous with pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
jRCT2031210049Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of isatuximab in multiple myeloma (MM) (4 arms), sponsored by Sanofi. Primary endpoints: Assessment of adverse events (AEs), Ceoi and 7 more. Started May 2021; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031210049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210049.